SELLAS Life Sciences Group, Inc. Common Stock (SLS)

Price$8.23

Value ScoreF

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)400.10%

Price vs S&P 500 (4W)64.28%

VGM Score46.08

Market Capitalization$1.53B

All Metrics

Book Value / Share (Quarterly)$0.59

P/TBV (Annual)4.32x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.16

Price vs S&P 500 (YTD)110.14%

Gross Margin (TTM)93.10%

Net Profit Margin (TTM)-736.21%

EPS (TTM)$-0.23

10-Day Avg Trading Volume10.52M

EPS Excl Extra (TTM)$-0.23

EPS (Annual)$-0.51

ROI (Annual)-327.52%

Gross Margin (Annual)90.00%

Net Profit Margin (5Y Avg)-1197.32%

Cash / Share (Quarterly)$0.59

ROA (Last FY)-159.53%

EBITD / Share (TTM)$-0.24

ROE (5Y Avg)-331.50%

Operating Margin (TTM)-730.69%

Cash Flow / Share (Annual)$-0.19

P/B Ratio14.25x

P/B Ratio (Quarterly)7.07x

Net Income / Employee (Annual)$-2,384,600

EV / Revenue (TTM)491.02x

Net Interest Coverage (TTM)-238.57x

ROA (TTM)-42.63%

EPS Incl Extra (Annual)$-0.51

Current Ratio (Annual)10.72x

Quick Ratio (Quarterly)16.60x

3-Month Avg Trading Volume7.36M

52-Week Price Return404.91%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.28

P/S Ratio (Annual)1531.05x

Asset Turnover (Annual)0.05x

52-Week High$9.51

Operating Margin (5Y Avg)-1281.81%

EPS Excl Extra (Annual)$-0.51

Tangible BV CAGR (5Y)52.96%

26-Week Price Return408.02%

Quick Ratio (Annual)10.28x

13-Week Price Return55.87%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)17.22x

Enterprise Value$1.42B

Asset Turnover (TTM)0.09x

Book Value / Share Growth (5Y)-17.33%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-4130.00%

Cash / Share (Annual)$0.47

3-Month Return Std Dev114.48%

Net Income / Employee (TTM)$-2,265,900

ROE (Last FY)-327.52%

Net Interest Coverage (Annual)-532.75x

EPS Basic Excl Extra (Annual)$-0.51

Receivables Turnover (TTM)4.46x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.23

Receivables Turnover (Annual)13.45x

ROI (TTM)-47.12%

P/S Ratio (TTM)527.95x

Pretax Margin (5Y Avg)-1213.64%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.28

Price vs S&P 500 (52W)380.54%

Year-to-Date Return118.30%

5-Day Price Return-9.26%

EPS Normalized (Annual)$-0.51

ROA (5Y Avg)-214.47%

Net Profit Margin (Annual)-4130.00%

Month-to-Date Return-11.60%

Cash Flow / Share (TTM)$-0.36

EBITD / Share (Annual)$-0.52

Operating Margin (Annual)-4195.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-331.50%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.23

P/TBV (Quarterly)4.31x

P/B Ratio (Annual)7.58x

Pretax Margin (TTM)-736.21%

Book Value / Share (Annual)$0.46

Price vs S&P 500 (13W)47.62%

Beta2.60x

Revenue / Share (TTM)$0.00

ROE (TTM)-47.12%

52-Week Low$1.39

vGradeF

mGradeA

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.05est. -0.04

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.14

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
SLSSELLAS Life Sciences Group, Inc. Common Stock	F	—	A	$8.23
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing immunotherapies and targeted cancer treatments. The company's pipeline includes galinpepimut-S, a peptide immunotherapy targeting the WT1 antigen, and GFH009, a selective CDK9 inhibitor. Both candidates address multiple cancer indications through distinct mechanisms of action.